Literature DB >> 1277711

Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect.

A Yacobi, J A Udall, G Levy.   

Abstract

The serum protein binding and elimination kinetics of warfarin were determined in 31 patients with cardiovascular disease who were taking warfarin regularly. The free fraction of warfarin in the serum ranged from 0.00436 to 0.0189, indicating 98.11% to 99.56% protein binding. There was no apparent relationship between the extent of protein binding of warfarin and the concentration of albumin or total protein in the serum. The estimated total body clearance of warfarin in the patients ranged from 1.16 to 4.35ml/hr/kg of body weight and correlated significantly with the free fraction of warfarin in serum. This correlation has been predicted on theoretical grounds and shows that serum protein binding is a major determinant of the elimination kinetics of warfarin in man and an important cause of interindividual variations in its body clearance. The interindividual variation of free warfarin concentrations in the serum of patients with similar prothrombin times was somewhat smaller than the variations in total serum-warfarin concentrations and in the daily dose of warfarin. There was no correlation between prothrombin time and the concentration of free warfarin in serum, indicating that variables other than protein binding also affect the anticoagulant response of patients.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1277711     DOI: 10.1002/cpt1976195part1552

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  51 in total

Review 1.  Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure.

Authors:  Andrea Lee; Mark Crowther
Journal:  J Thromb Thrombolysis       Date:  2011-04       Impact factor: 2.300

Review 2.  The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part II).

Authors:  W L Chiou
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

Review 3.  Protein binding drug displacement interactions fact or fiction?

Authors:  J J MacKichan
Journal:  Clin Pharmacokinet       Date:  1989-02       Impact factor: 6.447

4.  Microdialysis sampling for determination of plasma protein binding of drugs.

Authors:  A M Herrera; D O Scott; C E Lunte
Journal:  Pharm Res       Date:  1990-10       Impact factor: 4.200

Review 5.  New anticoagulants: how to deal with treatment failure and bleeding complications.

Authors:  Rashid S Kazmi; Bashir A Lwaleed
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

Review 6.  Diseases and drug protein binding.

Authors:  J P Tillement; F Lhoste; J F Giudicelli
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

7.  Interaction of clofibrate with warfarin. I. Effect of clofibrate on the disposition of the optical enantiomorphs of warfarin.

Authors:  T D Bjornsson; P J Meffin; T F Blaschke
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

Review 8.  Protein binding and kinetics of drugs in liver diseases.

Authors:  T F Blaschke
Journal:  Clin Pharmacokinet       Date:  1977 Jan-Feb       Impact factor: 6.447

9.  Discovery of allosteric modulators of factor XIa by targeting hydrophobic domains adjacent to its heparin-binding site.

Authors:  Rajesh Karuturi; Rami A Al-Horani; Shrenik C Mehta; David Gailani; Umesh R Desai
Journal:  J Med Chem       Date:  2013-03-18       Impact factor: 7.446

10.  Effect of nebicapone on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

Authors:  Luis Almeida; Amílcar Falcão; Manuel Vaz-da-Silva; Teresa Nunes; Ana-Teresa Santos; José-Francisco Rocha; Carla Neta; Tice Macedo; C Fontes-Ribeiro; P Soares-da-Silva
Journal:  Eur J Clin Pharmacol       Date:  2008-08-06       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.